Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

Abstract

PURPOSE To define the maximum-tolerated dose (MTD) and the phase II recommended dose (RD) of ecteinascidin-743 (ET-743) given as a 24-hour continuous infusion every 3 weeks to patients with treatment-refractory solid tumors. PATIENTS AND METHODS Fifty-two patients received a total of 158 cycles of ET-743 at one of nine dose levels (DLs) ranging from 50 to… (More)

Topics

Cite this paper

@article{Taamma2001PhaseIA, title={Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.}, author={Abdelkrim Taamma and J. L. Misset and Mar{\'i}a L Riofr{\'i}o and Carlos Guzm{\'a}n and {\'E}tienne Brain and Luis L{\'o}pez L{\'a}zaro and Howard Rosing and Jos{\'e} Mar{\'i}a Jimeno and Esteban Cvitkovic}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2001}, volume={19 5}, pages={1256-65} }